Related Experiment Videos
Replacement therapy for breast cancer survivors. A pilot study
P J DiSaia1, E A Grosen, F Odicino
1Department of Obstetrics and Gynecology, University of California at Irvine, College of Medicine, Orange 92668, USA.
Cancer
|November 15, 1995
Summary
This study found no significant adverse outcomes for breast cancer survivors using hormone replacement therapy (HRT). Further research, including randomized trials, is recommended to re-evaluate HRT for this population.
Area of Science:
- Oncology
- Endocrinology
Background:
- Historically, breast cancer survivors were excluded from hormone replacement therapy (HRT) due to concerns about disease recurrence.
- The potential for HRT to activate occult metastatic sites posed a risk to patient outcomes.
Purpose of the Study:
- To evaluate the safety and outcomes of hormone replacement therapy (HRT) in breast cancer survivors.
- To determine if HRT use is associated with adverse events or disease recurrence in this patient group.
Main Methods:
- A retrospective review was conducted on 77 breast cancer survivors who underwent HRT.
- Data analysis included correlations with cancer stage, patient age, and lymph node and receptor status.
Main Results:
- Seven recurrences were observed among the 77 patients analyzed.
- No recurrences were reported in an additional 33 patients added post-analysis.
- No significant adverse outcomes were detected in the overall group of breast cancer survivors receiving HRT.
Conclusions:
- Hormone replacement therapy (HRT) did not appear to cause significant adverse outcomes in this cohort of breast cancer survivors.
- The established benefits of HRT warrant a re-evaluation of its use in breast cancer survivors.
- A prospective randomized trial is crucial to definitively assess the safety and efficacy of HRT in this population.